Exchange: NYSE·Updated 07:45 PM EDT
News
all
press releases
Exploring Analyst Estimates for Agilent (A) Q3 Earnings, Beyond Revenue and EPS
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Agilent (A), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended July 2026.
Zacks
More News
MDT vs. A: Which Stock Should Value Investors Buy Now?
MDT vs. A: Which Stock Is the Better Value Option?
Zacks
Are Medical Stocks Lagging Adicet Bio (ACET) This Year?
Here is how Adicet Bio, Inc. (ACET) and Agilent Technologies (A) have performed compared to their sector so far this year.
Zacks
BioLife Solutions, Inc. (BLFS) Q2 Earnings and Revenues Surpass Estimates
BioLife Solutions (BLFS) delivered earnings and revenue surprises of +500.00% and +1.48%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Envista (NVST) Q2 Earnings and Revenues Surpass Estimates
Envista (NVST) delivered earnings and revenue surprises of +24.24% and +2.17%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Are Options Traders Betting on a Big Move in Agilent Technologies Stock?
Investors need to pay close attention to A stock based on the movements in the options market lately.
Zacks
Strength Seen in Kestra Medical Technologies, Ltd. (KMTS): Can Its 8.1% Jump Turn into More Strength?
Kestra Medical Technologies, Ltd. (KMTS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Zacks
DENTSPLY SIRONA to Post Q2 Earnings: What's in Store for the Stock?
XRAY's Q2 results are likely to reflect transformation investments, dealer inventory cuts and weak implants, while Wellspect growth offers support.
Zacks
Cencora to Report Q3 Earnings: Is a Beat Likely for the Stock?
COR's Q3 results could reflect specialty pharma strength, oncology expansion and margin gains, even as pricing dynamics and GLP-1 trends pressure revenues.
Zacks
Solventum to Report Q2 Earnings: What's in Store for the Stock?
SOLV's Q2 results are likely to benefit from segment strength, Acera gains and cost savings, offset by tariffs and ERP-related sales timing shifts.
Zacks

Advertisement|Remove ads.